45家医院505例体外膜氧合支持的2019冠状病毒病患者多机构分析:生存预测因素
该多机构数据库回顾了45家医院505例确诊2019冠状病毒病并接受体外膜氧合支持的患者,采用贝叶斯混合效应逻辑回归评估死亡危险因素。体外膜氧合中位时间18天,194例(38.4%)存活;静脉-静脉体外膜氧合存活184/466例(39.5%),静脉-动脉体外膜氧合存活8/30例(26.7%)。校正混杂后,诊断至插管第14天vs第4天相对生存比值比0.65(95%可信区间0.44-0.96),年龄57岁vs38岁相对生存比值比0.43(95%可信区间0.30-0.61)。
要点
- 505例中194例(38.4%)存活,静脉-静脉体外膜氧合存活184/466例(39.5%)。
- 存活者中位年龄更小(44 vs 51岁,P<.001),诊断至插管中位时间更短(7 vs 11天,P=.001)。
- 校正混杂后,诊断至插管第14天vs第4天相对生存比值比0.65(95%可信区间0.44-0.96)。
核心结论
- 体外膜氧合有助于部分危重2019冠状病毒病患者的挽救与存活,存活者往往更年轻且诊断至插管时间更短。
- 仅接受静脉-静脉体外膜氧合支持的患者存活率为39.5%。
研究设计与样本
- 多机构数据库回顾性分析45家医院505例确诊2019冠状病毒病并接受体外膜氧合支持的患者。
- 采用贝叶斯混合效应逻辑回归模型评估年龄、诊断至插管天数、插管至体外膜氧合启动天数等死亡危险因素对生存的影响。
主要发现
- 体外膜氧合中位时间18天(四分位距10-29天),505例全部脱离体外膜氧合,194例(38.4%)存活,311例(61.6%)死亡。
- 静脉-静脉体外膜氧合存活184/466例(39.5%),静脉-动脉体外膜氧合存活8/30例(26.7%)。
- 存活者中位年龄44岁vs死亡者51岁(P<.001),诊断至插管中位时间7天vs11天(P=.001)。
- 校正混杂后,诊断后第14天插管vs第4天插管的相对生存比值比0.65(95%可信区间0.44-0.96;负面效应后验概率98.5%)。
- 57岁患者vs38岁患者的相对生存比值比0.43(95%可信区间0.30-0.61;负面效应后验概率>99.99%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We reviewed our experience with 505 patients with confirmed coronavirus disease-2019 (COVID-19) supported with extracorporeal membrane oxygenation (ECMO) at 45 hospitals and estimated risk factors for mortality. METHODS: A multi-institutional database was created and used to assess all patients with COVID-19 who were supported with ECMO. A Bayesian mixed-effects logistic regression model was estimated to assess the effect on survival of multiple potential risk factors for mortality, including age at cannulation for ECMO as well as days between diagnosis of COVID-19 and intubation and days between intubation and cannulation for ECMO. RESULTS: Median time on ECMO was 18 days (interquartile range, 10-29 days). All 505 patients separated from ECMO: 194 patients (38.4%) survived and 311 patients (61.6%) died. Survival with venovenous ECMO was 184 of 466 patients (39.5%), and survival with venoarterial ECMO was 8 of 30 patients (26.7%). Survivors had lower median age (44 vs 51 years, P < .001) and shorter median time interval from diagnosis to intubation (7 vs 11 days, P = .001). Adjusting for several confounding factors, we estimated that an ECMO patient intubated on day 14 after the diagnosis of COVID-19 vs day 4 had a relative odds of survival of 0.65 (95% credible interval, 0.44-0.96; posterior probability of negative effect, 98.5%). Age was also negatively associated with survival: relative to a 38-year-old patient, we estimated that a 57-year-old patient had a relative odds of survival of 0.43 (95% credible interval, 0.30-0.61; posterior probability of negative effect, >99.99%). CONCLUSIONS: ECMO facilitates salvage and survival of select critically ill patients with COVID-19. Survivors tend to be younger and have shorter time from diagnosis to intubation. Survival of patients supported with only venovenous ECMO was 39.5%.
引用
- Hall CA, Jacobs JP, Stammers AH, et al. Multi-institutional Analysis of 505 Patients With Coronavirus Disease-2019 Supported With Extracorporeal Membrane Oxygenation: Predictors of Survival. Ann Thorac Surg. 2022. PMID: 35189111. doi:10.1016/j.athoracsur.2022.01.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。